Union Balanced Advantage Fund
The scheme seeks to achieve long term capital appreciation and generate income through an equity portfolio by using long equities, equity derivatives and arbitrage opportunities available.
Growthvine rating: 2/5 — ranked #26 of 35 in category.
Fund basics
| Category | Hybrid: Balanced Advantage |
|---|
| NAV | ₹20.76 (as of 2026-08-21) |
|---|
| AUM | ₹1,237 Cr |
|---|
| Expense ratio | 1.86% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Sanjay Bembalkar |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 7.56% |
|---|
| Sharpe ratio | 0.24 |
|---|
| Standard deviation | 8.84% |
|---|
| Max drawdown | -23.77% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 93.5% of NIFTY 50 Hybrid Composite Debt 50:50 Index's upside and 92.0% of its downside.
Market cap allocation
| Large cap | 61.1% |
|---|
| Mid cap | 18.0% |
|---|
| Small cap | 20.9% |
|---|
Concentration
| Top 5 holdings | 18.4% |
|---|
| Top 10 holdings | 26.7% |
|---|
| Total holdings | 77 |
|---|
Top holdings
- TREPS — 6.6%
- HDFC Bank Ltd. — 4.7%
- ICICI Bank Ltd. — 4.0%
- Bharti Airtel Ltd. — 3.7%
- State Bank Of India — 3.0%
- Reliance Industries Ltd — 2.9%
- Net Receivable / Payable — 2.1%
- Indian Railway Finance Corporation Ltd. — 2.0%
- National Bank for Agriculture and Rural Development — 2.0%
- Small Industries Development Bank of India — 2.0%
Top sectors
- Banking & Financial — 17.1%
- Pharma & Biotech — 5.4%
- Automobile — 5.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 0.4% | Q3 | #21 of 35 |
| 2025 | 5.8% | Q3 | #18 of 34 |
| 2024 | 10.0% | Q4 (Bottom) | #26 of 30 |
| 2023 | 15.5% | Q4 (Bottom) | #22 of 26 |
| 2022 | 2.5% | Q3 | #13 of 21 |